Spero Therapeutics, Inc. Announces Step Down of David P. Southwell from its Board of Directors
April 18, 2019 at 10:03 pm
Share
On April 18, 2019, David P. Southwell notified Spero Therapeutics, Inc. of his decision to step down from the Company's Board of Directors effective as of April 25, 2019. Mr. Southwell is stepping down from the Board as a result of contractual obligations he has taken on in conjunction with his appointment as CEO of another operating company. Mr. Southwell's decision to resign is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.